Ataluren | PTC124 | CFTR | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / 膜转运蛋白 / CFTR / Ataluren

阿塔鲁伦 /Ataluren 98%

货号：A306827 同义名： PTC124

PTC-124 is nonsense allele inhibitor, used to treat Duchenne muscular dystrophy.

Ataluren 化学结构
CAS号：775304-57-9

Ataluren 3D分子结构
CAS号：775304-57-9

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Ataluren 纯度/质量文件产品仅供科研

货号：A306827 标准纯度： 98% 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell,2024. Ambeed. [ A125712 ]; • Cancer Discov., 2024. Ambeed. [ A285925 ]; • JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]; • JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]; • EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]; 更多 >

CFTR 亚型比较

产品名称	CFTR ↓ ↑	纯度
Ataluren	✔	98%
Lumacaftor	++++ F508del-CFTR, EC50: 0.1 μM	98%
CFTR(inh)-172	+++ CFTR, Ki: 300 nM	99%+
GlyH-101	+ CFTR, Ki: 4.3 μM	99%+
IOWH-032	++ CFTR, IC50: 1.01 μM	99%+
Tezacaftor	✔	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Ataluren 生物活性

靶点

CFTR

描述

Nonsense mutations have been implicated in numerous inherited diseases and several cancers. For example, cystic fibrosis (CF) is a common autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. PTC-124 is an orally bioavailable compound that promotes readthrough of premature translation termination codons, suggesting its potential to treat genetic diseases caused by nonsense mutations like mutations in CFTR^[3]. The minimal concentration of PTC-124 showing discernable readthrough was 0.01–0.1 μM (2.8-28 ng/ml). And it promoted dose-dependent readthrough of all three nonsense codons in stable cell lines harbouring LUC-190 nonsense alleles^[4]. In a mouse model with CF, s.c. injection or oral administration of PTC-124 (60 mg/kg) to Cftr-/- mice expressing a human CFTR-G542X transgene suppressed the G542X nonsense mutation and restored a significant amount of human (h)CFTR protein and function. In addition, PTC-124 (60 mg/kg by s.c. injection or a liquid diet containing 0.9 mg/ml PTC-124) treatment restored 24-29% of the average cAMP-stimulated transepithelial chloride currents observed in wild-type mice. These results indicate that PTC-124 can effectively suppress the hCFTR-G542X nonsense mutation in vivo^[3].

Ataluren 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
BAC_MMA∗EGFP	20 μM	Function Assay	72 h	results in a significant increase in median peak fluorescence	23041189
HEK293T	10 µg/ml	Function Assay		restores full-length harmonin a1 (∼80 kDa) in p.R31X-transfected cells	23027640
ML1	3.3/10 μM	Function Assay	48 h	increases ARSB activity	22971959
ML2	3.3/10 μM	Function Assay	48 h	increases ARSB activity	22971959

Ataluren 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03256799	Cystic Fibrosis	Phase 4	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35233 收起 <<
NCT02139306	Cystic Fibrosis	Phase 3	Unknown	November 2016	-
NCT01182324	-		Completed	-	United States, Maryland ... 展开 >> National Human Genome Research Institute (NHGRI), 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<

Ataluren 参考文献

[1]105(6):2064-9

[2]447(7140):87-91

Ataluren 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

3.52mL

0.70mL

0.35mL

17.59mL

3.52mL

1.76mL

35.18mL

7.04mL

3.52mL

Ataluren 技术信息

CAS号	775304-57-9
分子式	C₁₅H₉FN₂O₃
分子量	284.242

别名	PTC124
运输	蓝冰

存储条件

粉末 Keep in dark place,Inert atmosphere,Room temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 50 mg/mL(175.91 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

IP 4% DMSO+2% Tween80+40% PEG300+water 1 mg/mL clear

PO 0.5% CMC-Na 22 mg/mL suspension

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03256799	Cystic Fibrosis	Phase 4	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35233 收起 <<
NCT02139306	Cystic Fibrosis	Phase 3	Unknown	November 2016	-
NCT01182324	-		Completed	-	United States, Maryland ... 展开 >> National Human Genome Research Institute (NHGRI), 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT02369731	-		Recruiting	April 2022	Austria ... 展开 >> Krankenhaus der Barmherzigen Schwestern Linz Recruiting Linz, Austria, 4010 Principal Investigator: Veronika Pilshofer, Dr Preyer Children Hospital Recruiting Wien, Austria, 1100 Principal Investigator: Guenther Bernert, Pr France CHU Brest, hôpital Morvan Recruiting Best, France, 29609 Principal Investigator: Ropars Juliette, Dr CHU Bordeaux Pelgrin Recruiting Bordeaux Cedex, France, 33076 Principal Investigator: Caroline Espil-Taris L'Escale Hôpital Femme Mère Enfant- Hospices Civils de Lyon Recruiting Bron, France, 69500 Principal Investigator: Carole Vuillerot, Dr CHU Clermont-Ferrand, hôpital Estaing Recruiting Clermont-Ferrand, France, 63003 Principal Investigator: Catherine Sarret, Dr CHU de Martinique - Hôpital P. Zobda-Quitman Recruiting Fort De France Cedex, France, 97261 Principal Investigator: Rémi Bellance, Dr CHRU de Lille Recruiting Lille Cedex, France, 59037 Principal Investigator: Jean-Marie Cuisset, Dr CHU Marseille Hôpital de la Timone Recruiting Marseille Cedex 5, France, 13385 Principal Investigator: Brigitte Chabrol, Pr CHU Nantes Recruiting Nantes, France, 44000 Principal Investigator: Yan Pereon, Pr Hôpital Armand Trousseau Recruiting Paris, France, 75012 Principal Investigator: Gidaro Teresa, Dr Hôpital Necker Recruiting Paris, France, 75015 Principal Investigator: Isabelle Desguerre, Pr CHU Reims Recruiting Reims, France, 51100 Principal Investigator: Pascal Sabouraud, Dr CHU Saint-Etienne MPR pédiatrique Hôpital Bellevue Recruiting Saint Etienne Cedex, France, 42055 Principal Investigator: Stéphane Chabrier, Dr CHU de la Réunion - GHSR - GH Sud-Réunion Recruiting Saint Pierre, France, 97448 Principal Investigator: Renouil Michel, Dr CHU Strasbourg Recruiting Strasbourg Cedex, France, 67098 Principal Investigator: Vincent Laugel, Pr CHU Toulouse Recruiting Toulouse, France, 31059 Principal Investigator: Pascal Cintas, Dr Hôpital d'enfants Gatien de Clocheville Recruiting Tours Cedex 9, France, 37044 Principal Investigator: Lagrue Emmanuelle, Dr CHU Nancy Hôpital de Brabois-Enfants Rue du Morvan Recruiting Vandoeuvre-les-Nancy, France, 54500 Principal Investigator: Emmanuel Raffo, Pr Germany Klinikum Bayreuth GmbH Recruiting Bayreuth, Germany, 95445 Principal Investigator: Almut Hirsch, Dr Charité Universitätsmedizin Berlin Recruiting Berlin, Germany, 13353 Principal Investigator: Claudia Weiss, Dr Universitätsklinikum Erlangen Recruiting Erlangen, Germany, 91054 Principal Investigator: Regina Trollmann, Pr Universitaetsklinikum Essen (AoR) Recruiting Essen, Germany, 45147 Principal Investigator: Ulrike Schara, Pr SPZ Frankfurt Mitte Recruiting Frankfurt am Main, Germany, 60316 Principal Investigator: Jurgen Seeger, Dr Universitaetsklinikum Freiburg Recruiting Freiburg, Germany, 79106 Principal Investigator: Janbernd Kirschner, Pr UKE, Universitätsklinikum Hamburg-Eppendorf Recruiting Hamburg, Germany, 20246 Principal Investigator: Jessica Johannsen, Dr Israel Hadassah Medical Center Recruiting Jerusalem, Israel, 91120 Principal Investigator: Talya Dor, Dr Chaim Sheba Medical Center Ramat Gan, Neuromuscle clinic Recruiting Ramat Gan, Israel, 52621 Principal Investigator: Amir Dori, Dr Sweden Queen Silvia Children's Hospital Recruiting Goteborg, Sweden, 41685 Principal Investigator: Mar Tulinius, Pr 收起 <<
NCT00237380	Cystic Fibrosis	Phase 2	Completed	-	Israel ... 展开 >> Hadassah University Hospital - Mount Scopus Jerusalem, Israel, 91240 收起 <<
NCT00458341	Cystic Fibrosis	Phase 2	Completed	-	Belgium ... 展开 >> Reine Fabiola Hospital Brussels, Belgium, 1020 UZ Gasthuisberg Leuven Leuven, Belgium, 3000 France Hopital Necker Enfants Malades Paris, France, 75015 收起 <<
NCT00264888	Duchenne Muscular Dystrophy	Phase 2	Completed	-	United States, Ohio ... 展开 >> Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229-3039 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104-4399 United States, Utah University of Utah Salt Lake City, Utah, United States, 84112 收起 <<
NCT03256968	Cystic Fibrosis	Phase 4	Active, not recruiting	December 31, 2018	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35233 收起 <<
NCT00234663	Cystic Fibrosis	Phase 2	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35233-1711 United States, California Stanford University Medical Center Palo Alto, California, United States, 94304-5786 United States, Colorado The Children's Hospital Denver, Colorado, United States, 80218 United States, Maryland Johns Hopkins Hospital Baltimore, Maryland, United States, 21287 United States, Ohio Rainbow Babies and Children's Hospital Cleveland, Ohio, United States, 44106 收起 <<
NCT03179631	Muscular Dystrophy, Duchenne ... 展开 >> Muscular Dystrophies Muscular Disorders, Atrophic Muscular Diseases Musculoskeletal Disease Neuromuscular Diseases Nervous System Diseases Genetic Diseases, X-Linked Genetic Diseases, Inborn 收起 <<	Phase 3	Recruiting	December 31, 2021	-
NCT02409004	Healthy	Phase 1	Completed	-	Canada ... 展开 >> Inventiv Quebec, Canada, G1P 0A2 收起 <<
NCT00351078	Cystic Fibrosis	Phase 2	Completed	-	Israel ... 展开 >> Hadassah University Hospital - Mount Scopus Jerusalem, Israel, 91240 收起 <<
NCT02647359	Aniridia	Phase 2	Active, not recruiting	December 2019	United States, Oregon ... 展开 >> Casey Eye Institute, Oregon Health & Science University Portland, Oregon, United States, 97239 United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22908 Canada, British Columbia University of British Columbia Vancouver, British Columbia, Canada, V5Z3N9 收起 <<
NCT00592553	Duchenne Muscular Dystrophy ... 展开 >> Becker Muscular Dystrophy 收起 <<	Phase 2	Completed	-	-
NCT01141075	Amino Acid Metabolism, Inborn ... 展开 >>Errors 收起 <<	Phase 2	Terminated	-	Belgium ... 展开 >> ZNA Queen Paola Child Hospital and Provincial Centre for Metabolic Disorders Antwerp, Belgium France Hôpital Edouard Herriot Lyon, France Necker-Enfants Malades Hospital Paris, France Germany University Children's Hospital Duesseldorf, Germany Italy Istituti Clinici di Perfezionamento, Milano Milan, Italy Federico II University Naples, Italy University Hospital, Department of Pediatrics Padova, Italy Switzerland University Children's Hospital Zürich, Switzerland United Kingdom Great Ormand Street Hospital London, United Kingdom 收起 <<
NCT00947193	Hemophilia A ... 展开 >>Hemophilia B 收起 <<	Phase 2	Suspended	May 2012	United States, Illinois ... 展开 >> The Bleeding and Clotting Disorders Institute Peoria, Illinois, United States, 61614 United States, Indiana St. Vincent Indianapolis Hospital Indianapolis, Indiana, United States, 46260 United States, Massachusetts New England Hemophilia Center Worcester, Massachusetts, United States, 01605 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Vanderbilt Hemostatis and Thrombosis Clinic Nashville, Tennessee, United States, 37232 United States, Washington Puget Sound Blood Center Seattle, Washington, United States, 98104 Canada, British Columbia St. Paul's Hospital Vancouver, British Columbia, Canada, V6Z 1Y6 France Hôpital Cardiologique Lille Cedex, France Hôpital Edouard Herriot Lyon Cedex, France Hôpital Necker Enfants Malades Paris, France Italy Azienda Ospedaliero-Universitaria Careggi Viale G.B. Morgagni Firenze, Italy A.Bianchi Bonomi Hemophilia and Thrombosis Center Milano, Italy 收起 <<
NCT01140451	Cystic Fibrosis	Phase 3	Completed	-	-
NCT01826487	Muscular Dystrophy, Duchenne ... 展开 >> Muscular Dystrophies Muscular Disorders, Atrophic Muscular Diseases Musculoskeletal Diseases Neuromuscular Diseases Nervous System Diseases Genetic Diseases, X-Linked Genetic Diseases, Inborn 收起 <<	Phase 3	Completed	-	-
NCT00759876	Duchenne Muscular Dystrophy	Phase 2	Terminated	-	United States, Ohio ... 展开 >> Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229-3039 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 United States, Utah University of Utah Salt Lake City, Utah, United States, 84112 收起 <<
NCT00803205	Cystic Fibrosis	Phase 3	Completed	-	-
NCT02758626	Epilepsy	Phase 2	Active, not recruiting	December 2022	United States, New York ... 展开 >> New York University School of Medicine New York, New York, United States, 10016 收起 <<
NCT01247207	Duchenne Muscular Dystrophy	Phase 3	Enrolling by invitation	December 31, 2018	United States, California ... 展开 >> University of California-Davis Sacramento, California, United States, 95817 United States, Colorado The Children's Hospital Aurora, Colorado, United States, 80045 United States, Florida Child Neurology Center of NW Florida Gulf Breeze, Florida, United States, 32561 United States, Iowa University of Iowa Children's Hospital Iowa City, Iowa, United States, 52242 United States, Kansas University of Kansas Medical Center Kansas City, Kansas, United States, 66160 United States, Massachusetts Children's Hospital of Boston/Harvard Medical School Boston, Massachusetts, United States, 02115 United States, Minnesota University of Minnesota Minneapolis, Minnesota, United States, 55455 United States, Missouri Washington University Medical School Saint Louis, Missouri, United States, 63110 United States, New York Columbia University Medical School New York, New York, United States, 10032 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio Cincinnati Childrens Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Oregon Shriners Hospital for Children-Portland Portland, Oregon, United States, 97239 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 United States, Texas Southwestern University Dallas, Texas, United States, 75207 United States, Utah University of Utah Salt Lake City, Utah, United States, 84112 收起 <<
NCT03648827	Duchenne Muscular Dystrophy	Phase 2	Not yet recruiting	February 29, 2020	United States, Arizona ... 展开 >> Phoenix Childrens Hospital Not yet recruiting Phoenix, Arizona, United States, 85016 Contact: Nakia Croft 602-933-0641 ncroft@phoenixchildrens.com Principal Investigator: Saunder Bernes United States, California University of California, Los Angeles (UCLA) Not yet recruiting Los Angeles, California, United States, 90025 Contact: Emilie Douine 310-267-2416 edouine@mednet.ucla.edu Principal Investigator: Stanley Nelson University of California (UC) Davis Medical Center Not yet recruiting Sacramento, California, United States, 95817 Contact: Omaid Sarwary 916-734-0968 omsarwary@ucdavis.edu Principal Investigator: Craig McDonald United States, Illinois Rush University Medical Center Not yet recruiting Chicago, Illinois, United States, 60612 Contact: Susan Rohde 312-942-0079 susan_rohde@rush.edu Principal Investigator: Peter Heydemann United States, Kansas University of Kansas Medical Center Not yet recruiting Kansas City, Kansas, United States, 66160 Contact: Katie Roath Principal Investigator: Jeffrey Statland United States, Minnesota University of Minnesota Not yet recruiting Minneapolis, Minnesota, United States, 55455 Contact: Natalya Alassy 612-626-4690 burla019@umn.edu Principal Investigator: Peter Karachunski United States, New York Columbia University College of Physicians & Surgeons Not yet recruiting New York, New York, United States, 10032 Contact: Ameneh Onativia 212-342-3679 am2959@cumc.columbia.edu Principal Investigator: Darryl De Vivo United States, Texas Texas Children's Hospital Not yet recruiting Houston, Texas, United States, 77030 Contact: Monica Garza 832-822-1255 mxgarza9@texaschildrens.org Principal Investigator: Tim Lotze University of Texas Heath Science Center at San Antonio Not yet recruiting San Antonio, Texas, United States, 78229-3900 Contact: Yogeet Kaur 210-567-8222 kaury@uthscsa.edu Principal Investigator: Ratna Bhavaraju-Sanka United States, Virginia Children's Hospital of the King's Daughters Not yet recruiting Norfolk, Virginia, United States, 23507 Contact: Terrie Karras Conklin 757-469-9123 terrie.conklin@chkd.org Principal Investigator: Crystal Proud 收起 <<
NCT00847379	Duchenne Muscular Dystrophy ... 展开 >> Becker Muscular Dystrophy 收起 <<	Phase 2 Phase 3	Terminated	-	-
NCT02456103	Cystic Fibrosis	Phase 3	Terminated(CF Data from CF stu... 展开 >>dy 021 did not meet end points) 收起 <<	-	-
NCT02819557	Duchenne Muscular Dystrophy	Phase 2	Completed	-	United States, Florida ... 展开 >> Child Neuro NWF Gulf Breeze, Florida, United States, 32561 United States, Illinois Rush University Medical Center Chicago, Illinois, United States, 60612 United States, Massachusetts Children's Hospital Boston Boston, Massachusetts, United States, 02115 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Texas Children's Medical Center Dallas Dallas, Texas, United States, 75390-8843 United States, Utah University of Utah Salt Lake City, Utah, United States, 84112 收起 <<
NCT01009294	Duchenne Muscular Dystrophy ... 展开 >> Becker Muscular Dystrophy 收起 <<	Phase 2	Terminated	-	United States, California ... 展开 >> University of California-Davis Davis, California, United States, 95616 United States, Massachusetts Children's Hospital of Boston Boston, Massachusetts, United States, 02115 United States, Minnesota University of Minnesota Minneapolis, Minnesota, United States, 55455 United States, Missouri Washington University Medical School Saint Louis, Missouri, United States, 63110 United States, Ohio Nationwide Children's Hospital Columbus, Ohio, United States, 43205 United Kingdom University of Newcastle Newcastle upon Tyne, United Kingdom, NE1 3BZ 收起 <<
NCT01557400	Duchenne Muscular Dystrophy ... 展开 >> Becker Muscular Dystrophy Dystrophinopathy 收起 <<	Phase 3	Active, not recruiting	March 2018	Australia, Melbourne ... 展开 >> Royal Children's Hospital Parkville, Melbourne, Australia Australia Institute For Neuromuscular Research, The Children's Hospital at Westmead Westmead, Australia Belgium University Hospital KU Leuven Leuven, Belgium Canada, Alberta Alberta Children's Hospital Calgary, Alberta, Canada Canada, British Columbia British Columbia Children's Hospital Vancouver, British Columbia, Canada Canada, Ontario Children's Hospital of Western Ontario London, Ontario, Canada France Hôpital d'Enfants CHU Timone Marseille, France Laboratoire d'Exploration Fonctionnelles Nantes, France Groupe Hospitalier La Pitie-Salpetriere Paris, France Germany University of Essen - Clinic for Children Essen, Germany University Hospital Freiburg, Germany Israel Hadassah Medical Center, Hebrew University Hospital Jerusalem, Israel Italy Ospedale Maggiore Policlinico in Milan Milan, Italy Ospedale Pediatrico Bambino Gesu Rome, Italy U.O. Complessa di Neuropsichiatria Infantile Rome, Italy Spain Hospital Sant Joan de déu Barcelona, Spain Hospital Universitari La Fe Valencia, Spain Sweden Queen Silvia Children's Hospital Göteborg, Sweden Astrid Lindgren Pediatric Hospital Stockholm, Sweden United Kingdom Great Ormond Street Hospital London, United Kingdom University of Newcastle Institute of Human Genetics Newcastle Upon Tyne, United Kingdom 收起 <<
NCT02107859	Cystic Fibrosis	Phase 3	Terminated(CF Data from CF stu... 展开 >>dy 021 did not meet end points.) 收起 <<	-	United States, Alabama ... 展开 >> University of Alabama-Birmingham Birmingham, Alabama, United States, 35233 United States, California Miller Children's Hospital Long Beach Long Beach, California, United States, 90806 United States, Colorado Denver Children's Hospital Aurora, Colorado, United States, 80045 United States, Illinois Children's Hospital Chicago Chicago, Illinois, United States, 60614 United States, Massachusetts Children's Hospital Boston Boston, Massachusetts, United States, 02115 United States, New York Beth Israel Medical Center New York, New York, United States, 10003 United States, Ohio Rainbow Babies & Children's Hospital Cleveland, Ohio, United States, 44106 Belgium Hôpital Universitaire des Enfants Reine Fabiola Brussels, Belgium University Hospital Brussels Brussels, Belgium University Hospital Leuven Leuven, Belgium France Hôpital Necker - Enfants Malades Paris, France Hôpital des Enfants Toulouse, France, 31059 Israel Hadassah University Hospital - Mount Scopus Jerusalem, Israel, 91240 Italy Università La Sapienza Roma, Italy Azienda Ospedaliera di Verona Verona, Italy Spain Hospital Universitario La Paz Madrid, Spain Sweden Karolinska University Hospital, Huddinge Stockholm, Sweden 收起 <<
NCT02090959	Muscular Dystrophy, Duchenne ... 展开 >> Muscular Dystrophies Muscular Disorders, Atrophic Muscular Diseases Musculoskeletal Diseases Neuromuscular Diseases Nervous System Diseases Genetic Diseases, X-Linked Genetic Diseases, Inborn 收起 <<	Phase 3	Active, not recruiting	June 2018	-

阿塔鲁伦 /Ataluren 98%

Ataluren 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Ataluren 质控信息

Ataluren 生物活性

Ataluren 细胞研究

Ataluren 临床研究

Ataluren 参考文献

Ataluren 实验方案

Ataluren 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

阿塔鲁伦 /Ataluren 98%

Ataluren 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Ataluren 质控信息

Ataluren 生物活性

Ataluren 细胞研究

Ataluren 临床研究

Ataluren 参考文献

Ataluren 实验方案

Ataluren 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Ataluren 纯度/质量文件产品仅供科研